Pfizer Inc. is closing in on a deal to acquire Medivation Inc. for about $14 billion, according to multiple reports. The deal may be announced as soon as Monday, according to the Financial Times, which first reported the possible deal. The purchase of the cancer-drug developer would significantly bolster Pfizer’s oncology business, led by Medivation’s popular prostate-cancer treatment, Xtandi.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News